ADAR1 Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

ADAR1 Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.3M	Sell	26,913 -1,815	-6%	-$80.4K	0.08%	139
2025 Q4	$1.19M	Sell	28,728 -46,459	-62%	-$1.86M	0.09%	124
2025 Q3	$2.92M	Buy	75,187 +18,647	+33%	+$606K	0.27%	64
2025 Q2	$1.56M	Buy	56,540 +15,128	+37%	+$385K	0.24%	65
2025 Q1	$920K	Sell	41,412 -124,994	-75%	-$2.57M	0.17%	83
2024 Q4	$3.29M	Sell	166,406 -270,262	-62%	-$6.17M	0.66%	34
2024 Q3	$10.9M	Buy	436,668 +322,359	+282%	+$7.85M	1.77%	12
2024 Q2	$2.13M	Buy	114,309 +54,609	+91%	+$1.02M	0.4%	42
2024 Q1	$1.18M	Sell	59,700 -45,300	-43%	-$885K	0.27%	57
2023 Q4	$1.84M	Buy	+105,000	New	+$1.73M	0.66%	31

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

ADAR1 Capital Management's KNSA Position: Q1 2026 in Review

ADAR1 Capital Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 6.3% in Q1 2026, selling an estimated $80.4K and leaving 26,913 shares worth $1.3M. The position accounts for 0.08% of the portfolio, ranked #139.

ADAR1 Capital Management first reported a position in KNSA in Q4 2023 and has held it in 10 quarters since. The position peaked at $10.9M in Q3 2024. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

ADAR1 Capital Management held 26,913 shares of Kiniksa Pharmaceuticals worth $1.3M as of Q1 2026.
ADAR1 Capital Management sold 1,815 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $80.4K.
Kiniksa Pharmaceuticals made up 0.08% of ADAR1 Capital Management's portfolio in Q1 2026, its #139 holding.
ADAR1 Capital Management first reported a position in Kiniksa Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
ADAR1 Capital Management's Kiniksa Pharmaceuticals position peaked at $10.9M in Q3 2024.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.